Jilin Aodong Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 4/6
Jilin Aodong Pharmaceutical Group has a total shareholder equity of CN¥29.3B and total debt of CN¥2.1B, which brings its debt-to-equity ratio to 7.3%. Its total assets and total liabilities are CN¥32.9B and CN¥3.6B respectively.
Key information
7.3%
Debt to equity ratio
CN¥2.13b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥2.97b |
| Equity | CN¥29.26b |
| Total liabilities | CN¥3.64b |
| Total assets | CN¥32.90b |
Recent financial health updates
No updates
Recent updates
We Think That There Are More Issues For Jilin Aodong Pharmaceutical Group (SZSE:000623) Than Just Sluggish Earnings
Nov 06
Market Might Still Lack Some Conviction On Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623) Even After 36% Share Price Boost
Oct 01A Look At The Intrinsic Value Of Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)
Aug 22Jilin Aodong Pharmaceutical Group (SZSE:000623) Is Increasing Its Dividend To CN¥0.60
Jul 05Investors Holding Back On Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)
Jun 03There Might Be More To Jilin Aodong Pharmaceutical Group's (SZSE:000623) Story Than Just Weak Earnings
Apr 23Financial Position Analysis
Short Term Liabilities: 000623's short term assets (CN¥5.3B) exceed its short term liabilities (CN¥2.4B).
Long Term Liabilities: 000623's short term assets (CN¥5.3B) exceed its long term liabilities (CN¥1.3B).
Debt to Equity History and Analysis
Debt Level: 000623 has more cash than its total debt.
Reducing Debt: 000623's debt to equity ratio has reduced from 9.3% to 7.3% over the past 5 years.
Debt Coverage: 000623's debt is not well covered by operating cash flow (14.4%).
Interest Coverage: Insufficient data to determine if 000623's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 03:15 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jilin Aodong Pharmaceutical Group Co., Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Weina Jiang | Everbright Securities Co. Ltd. |
| Lei Pan | Guodu Securities Co. |
| null Research Department | Guotai Junan International Holdings Limited |